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Abstract
Perlecan/Hspg2 (Pln) is a large heparan sulfate proteoglycan abundant in the extracellular matrix
of cartilage and the lacuno-canalicular space of adult bones. While Pln function during cartilage
development is critical, evidenced by deficiency disorders including Schwartz-Jampel Syndrome
and dyssegmental dysplasia Silverman-Handmaker type, little is known about its function in
development of bone shape and quality. The purpose of this study was to understand the
contribution of Pln to bone geometric and mechanical properties. We used hypomorph mutant
mice that secrete negligible amount of Pln into skeletal tissues and analyzed their adult bone
properties using micro-computed tomography and three-point-bending tests. Bone shortening and
widening in Pln mutants was observed and could be attributed to loss of growth plate organization
and accelerated osteogenesis that was reflected by elevated cortical thickness at older ages. This
effect was more pronounced in Pln mutant females indicating a gender-specific effect of Pln
deficiency on bone geometry. Additionally, mutant females, and to a lesser extent mutant males,
increased their elastic modulus and bone mineral densities to counteract changes in bone shape,
but at the expense of increased brittleness. In summary, Pln deficiency alters cartilage matrix
patterning and, as we now show, coordinately influences bone formation and calcification.
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Introduction
Perlecan/Hspg2 (Pln) is a large heparan sulfate (HS) proteoglycan found in the territorial
matrix of mammalian cartilage as well as in basement membranes [1, 2]. Pln disappears at
the chondro-osseous junction during endochondral ossification, the process underlying long
bone development whereby a cartilage anlagen is replaced by bone and marrow. Deficiency
of Pln in developing null mouse embryos leads to severe heart, brain, and skeletal dysplasias
that are responsible for death between embryonic stage E10.5 and birth [3, 4]. In humans,
functional null mutations in the PLN gene result in lethal forms of neonatal short-limbed
dwarfism known as dyssegmental dysplasia Silverman-Handmaker type (DDSH) syndrome
(MIM# 224410) and characterized by severe cartilage matrix anomalies. In contrast,
Schwartz-Jampel syndrome type 1 (SJS1; MIM# 255800) patients affected by hypomorphic
mutations in the PLN gene, display a less severe short stature phenotype accompanied by
chondrodysplasias, myotonic myopathy, and facial and ocular abnormalities. The difference
of severity between SJS and DDSH appears to result from variations in residual Pln
expression, as no secreted Pln was detected in fibroblasts of DDSH patients and
immunostaining on SJS patient’s fibroblasts showed considerable reduction of Pln within
the extracellular matrix but not functional null mutation of Pln [5, 6].
Although Pln is a multifunctional extracellular proteoglycan with scaffolding properties, its
best characterized function is to modulate heparin binding growth factors (HBGFs)
availability during bone development [7]. In this regard, Pln NH2-terminal domain carrying
HS chains can be used to engineer biomaterials capable of releasing HBGFs, such as BMPs,
in a controlled manner for joint tissue repair applications [1, 8, 9].
Bone is a supercomposite material that includes a cartilaginous part and an osseous part
made of an organic phase and an inorganic phase and the relative amount and structure of
these two phases determines its quality. Although toughness of bone is primarily derived
from the mineral phase, interactions with the organic phase are essential for its unique
elastic material properties [10]. During bone development, regulated production of
extracellular matrix (ECM) components establishes normal bone mass and architecture [11].
Both ECM proteins and proteoglycans present in bone have been proposed to play
regulatory roles in the process of mineralization and hydroxyapatite crystal growth [12-16].
Additionally, recent studies from our laboratories proposed that Pln and its associated HS
chains present at high concentrations in differentiated cartilage aid in the prevention of
tissue mineralization during chondrogenesis, help maintain the pericellular space of
osteocytes, and regulate solute transport and mechanosensing in adult cortical bone [2, 17,
18].
In this study, we used a viable Pln hypomorph mutant mouse model that displays a
phenotype consistent with SJS patients to investigate the functional role of Pln in the
regulation of bone formation and mineralization in vivo [19]. We hypothesized that absence
of Pln permits premature turnover of hypertrophic cartilage to osseous bone in the growth
plate, which, in turn, results in short stature and increased skeletal fragility. This idea is
consistent with the abrupt loss of Pln at the chondro-osseous junction seen during normal
development, and tests further the hypothesis that Pln is required for normal bone patterning
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during development. To test this idea, we used osteoprogenitors from Pln-deficient
developing embryos and compared their differentiation potential to control cells.
Additionally, we examined the consequences of Pln deficiency on bone geometry and
mechanical properties in adult mice.
Methods
Animals and Statistics
Bones were obtained from Hspg2C1532Yneo homozygous (Pln mutant), heterozygous or wild
type (WT) mice of the C57BL6/J background [19]. WT and heterozygous mice did not
exhibit a distinct phenotype. All results are expressed as mean ±SD. Statistical comparisons
between genotypes were performed using a two-tailed Student’s t-test and p values less than
0.05 were considered significant. All animal experiments were performed in accordance
with IACUC approved protocols.
Immunohistochemistry
Data for multilabeling were acquired by confocal microcopy as described [20]. Newborn
femoral growth plate cryosections were immunostained using rabbit polyclonal antibodies
directed against Pln/Hspg2 (1:200 dilution; LifeSpan Biosciences Inc.), the ER marker BiP
(1:400 dilution; Abcam), type X collagen (1:200, dilution, Dr. W.A. Horton, Shriners
Hospital, Portland, OR) or another major proteoglycan secreted by chondrocytes, aggrecan
(1:100 dilution; Millipore) as described [21]. For von Kossa staining, PN1 tibiae sections
were fixed in 95% ethanol for 15 minutes and incubated in 5% (w/v) silver nitrate solution
under ultra-violet light for 30 min.
Differentiation Assay
Mouse embryonic cells were isolated from E14.5 embryos obtained from Pln mutant and
WT matings as described [20]. For differentiation, 2.5×105 cells were plated onto
gelatinized 6-well plates (35mm) in the presence or absence of 100ng/ml BMP-2 (R&D
Systems, Minneapolis, MN) in medium composed of DMEM (Invitrogen), 10% (v/v) fetal
bovine serum (Hyclone, Logan, UT), 2mM L-glutamine (Invitrogen), 10-4 M β
mercaptoethanol (Sigma-Aldrich), 5mM β-glycerophosphate, 50 μg/ml ascorbic acid, and
penicillin and streptomycin at 50μg/mL each. Medium was changed every other day and
alkaline phosphatase staining was performed after nine days of culture according to the
manufacturer’s instructions (Chemicon International, Temecula, CA). For mineralization
assessment, von Kossa staining was performed on day 12 cultures as indicated above for
tibiae sections. Experiments were performed using quadruplate samples and were repeated
three times.
Ash Content
The proximal and distal regions from six month-old Pln mutant and WT femora were cut
away using a diamond saw to remove the marrow in PBS, leaving only cortical bone. The
dry mass of each femur was obtained after drying at 85°C for 18 hrs. Ash weight was
determined after heating individual dry bones in a furnace at 600°C for 18hrs.
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Micro-Computed (μCT) Tomography
Three and six-month-old femora of the same genotype and gender were scanned
simultaneously at a resolution of 27μm for 7hrs using a preclinical μCT Scanner (GE
Healthcare Bio-Sciences Corp.), and images were analyzed using the GE Microview
software as described [11]. To obtain bending moment of inertia, the cross-section image at
the middle plane of the ROI used for μCT was converted to a binary image, and the center of
mass was identified to calculate the principal moments of inertia (IAP, IML) as described
[11]. The cortical width was determined by measuring the distance between eight pairs of
points that were spanning the periosteal and endosteal surfaces of the cortical bone at mid-
shaft.
Biomechanical Testing
Tests were performed on six month-old femora using a mechanical MicroTester (Instron
5848). Each bone was tested in a three-point bending fixture with a support span of 4.5 mm.
The actuator was advanced at 0.05mm/s, compressing the bone in the anterior-posterior
(AP) direction until failure as described [11]. Stiffness (S), ultimate force, and post-yield
displacement (PYD) were derived from load-displacement curves and bending rigidity (EI)
was calculated using S and the simply-supported beam equation as described [22]. The
principle moment of inertia relative to the medial-lateral axis, (IML), was used in the
calculation of the Young’s modulus (E).
Results
Effects of Pln Hypomorphic Mutation on Osteogenesis
At birth, Pln mutant bones derived on the C57BL6/J background were increased in width
compared with background-matched control littermates (Table 1 and compare arrows in Fig.
1A&F). In addition, newborn growth plates showed a more diffuse and irregular
organization of the hypertrophic zone in the Pln mutant compared to WT mice (Figs.1&2).
Furthermore, the Pln mutant hypertrophic chondrocytes lack the packed and tight columnar
organization of the territorial matrix seen in the hypertrophic zone of control bones
(compare D and I in Fig.1). However, the most striking feature of the developing Pln mutant
bones is the marked decrease of Pln-positive cartilage matrix compared to the control bones
(Fig.1 compare A-C to F-H). Additionally, most of the Pln translated by the mutant
chondrocytes was retained intracellularly rather than secreted pericellularly into the ECM
(compare B and G in Fig.1). Pln intracellular retention in hypertrophic chondrocytes
occurred in the endoplamic reticulum (ER) as demonstrated by its perinuclear co-
localization with the ER chaperone, BiP (Fig.1H). Western blot analysis of protein lysates
extracted from both WT and Pln mutant primary chondrocytes revealed that there is no
significant change in BiP protein levels in Pln mutants versus controls (Fig.1S). The small
accumulation of Pln in the ER of mutant chondrocytes did not influence secretion levels of
aggrecan, another proteoglycan important in cartilage function (compare E to J in Fig.1).
The absence of Pln in the extracellular matrix, however, altered overall matrix organization
in the prehypertrophic and hypertrophic zones of mutant bones (compare D to I in Fig.1).
Immunolocalization of type X collagen and von Kossa staining on adjacent sections of both
Pln mutant and WT growth plates revealed the presence of an expanded hypertrophic zone
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(compare arrows in Fig.2A and C) which overlaps with mineral deposits (compare arrows in
Fig.2B and D) in Pln mutants (Fig.2C-D). In contrast, WT growth plates displayed a clear
demarcation at the chondro-osseous junction between the hypertrophic zone and the
mineralization front (Fig.2A-B). Interestingly, analysis of postnatal growth plates revealed
that the rate of proliferation in Pln mutant growth plates is decreased compared to wild type
(Fig.2S). Together, these results indicate an overall decreased proliferation associated with
increased terminal differentiation and calcification in mutant relative to wild type growth
plates.
To further characterize the role played by secreted Pln during bone development, in vitro
differentiation assays were conducted using primary cultures of mouse embryonic cells (Fig.
3). WT cells secreted large levels of Pln extracellularly whereas Pln mutant cells only
expressed small levels of Pln intracellularly (Fig.3, compare A to B). The lack of Pln
secretion in Pln mutant progenitors dramatically enhanced their endogenous differentiation
potential into differentiated osteoblasts when compared with control WT cells (Fig.3C-D).
This observation shows for the first time that functional absence of Pln in the extracellular
matrix of osteoblast progenitors is conducive to osteogenesis. This effect is even more
pronounced when cells were cultured in the presence of the differentiation growth factor,
BMP2 (Fig.3E-F). Moreover, terminal differentiation and mineral nodule deposition was
observed in the presence of BMP2 in Pln mutant cultures but not in WT controls (Fig.3J),
suggesting that the absence of Pln promotes BMP2 activity. Consistent with this data,
comparison of the transcriptional profile of mouse embryonic cells revealed that markers of
osteoblast differentiation such as alkaline phosphatase (Alpl), osteocalcin (Bglap1), and
phosphate regulating endopeptidase homolog, X-linked (Phex), were significantly increased
in BMP2-treated Pln mutant cultures relative to control cultures subjected to the same
culture conditions (Fig.3S). Additionally, BMP-2 treated perlecan deficient cells secreted
elevated levels of ostecalcin in the culture media compared to BMP2-treated wild type
control cells (data not shown). Finally, no significant change in osteoclast differentiation and
bone resorption potentials were found in Pln mutants relative to wild type controls when
primary osteoclasts isolated from spleens were induced to differentiate and grown on bone
slices in the presence of osteoclast differentiation media (data not shown).
Skeletal phenotype in Adult Pln-deficient Mice
To compare the rates of growth of Pln mutant and control mice, the mouse weights were
collected during post-weaning life (Fig.4A). The growth curves show that the average
weight of Pln-deficient mutants diverge significantly from their wild-type and heterozygote
siblings. This difference in body weight between controls and Pln mutant corresponded to an
approximate 20% decrease in mutants vs. WT at 2.5 months (nine weeks) for both males
(p<0.001) and females (p<0.05). Interestingly, this decrease became more pronounced and
reached approximately 25% and 30% at 5-6 months (20-24 weeks) of age in males and
females, respectively (p<0.001 in mutants vs. WT). Additionally, pronounced ischium/hip
deformities and shortening/widening of long bones and vertebrae were apparent in Pln
mutants relative to controls (Fig.4B). Interestingly, the significant decrease (-10% in mutant
vs. WT, p<0.05) in the total length of Pln mutant tibiae and femora in both males and
females was not accompanied by a corresponding decrease in the wet weight of mutant
Lowe et al. Page 5
Calcif Tissue Int. Author manuscript; available in PMC 2015 July 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
bones when compared with WT controls (Fig.4D&E). Analysis of mid-shaft cross-sections
revealed a significant increase in bone cortical area in Pln mutants when compared to
controls that was found to be more pronounced in female (+29%) vs. male (+12%) mutants
(Table 1; Fig.4C). Accordingly, the outer perimeter and cortical width were also increased in
Pln mutants when compared with control bones, with significant increases only in mutant
females (Table 1, +7.2% and +19.5%, respectively). In contrast, the external antero-
posterior (A/P) bone diameters were similarly increased in both males (+16%, p<0.05) and
females (+11%, p<0.05). Nonetheless, the M/L and A/P moments of inertia (IML and IAP),
which represent bending resistance, were significantly increased exclusively in females
(IML, +46.4% and IAP, +37.5%) when compared to WT controls (Table 1; Fig.4C). Because
Pln mutant bones demonstrated an increase in their ash mass/dry mass percentage (74.3%
±1.6 SD, n=15) relative to WT bones (72.9%±2.7 SD; n=13) that nearly reached
significance (p=0.105), the more sensitive micro-CT approach was employed to determine
how Pln deficiency affects bone mineral composition. Indeed, increases in mineral density
(BMD) and mineral content (BMC) in Pln mutants vs. controls were found for both females
(+9.1% for BMD, 40.2% for BMC) and males (+8.3% for BMD, +20.7% for BMC) when a
micro-CT analysis of cortical bone was used. Interestingly, BMD and BMC, usually lower
in females relative to males in WT, were found to be identical in Pln mutant males when
compared to Pln mutant females (Table 1). In contrast, no significant change in cortical bone
mineral parameters was found in younger Pln mutant animals of both genders relative to
gender-matched WT controls when compared at three months of age (data not shown).
Mechanical Testing of Pln-deficient bones
Whereas Pln-deficient femora bending rigidity was hardly increased in males, their strength
was elevated by approximately 2-fold in females relative to age-matched controls (Fig.5A,
+125%, p<0.05). As expected from changes in geometrical properties, both males and
females mutant bones demonstrated a significant increase in ultimate force relative to
controls (Fig.5B). Yet, elevated structural properties at mid-shaft allowed Pln mutant
females to withstand higher forces than Pln mutant males vs. WT controls (+75.6% and
+32.9%, respectively, p<0.05). These results are in agreement with the more pronounced
structural changes seen in mutant female cortical bones when compared to mutant males. In
addition, increased cortical BMD in Pln mutants resulted in higher energy to bend them to
failure when compared to controls (Table 1, Fig.5D). Whereas, the post-yield deflection
(PYD) was not significantly altered in males, female’s PYD was significant smaller (Fig.
5C). Only females displayed a significantly higher elastic modulus (E) vs. controls (Fig.5F,
+55.2%, p<0.05).
Discussion
Whereas functional null mutations of the Pln/Hspg2 gene were reported to develop severe
chondrodysplasias, the phenotype of mice expressing reduced amounts of Pln resembles SJS
patients and displays growth plate defects, short stature, distinct facial features and other
progressive skeletal defects [3, 4, 19]. A consequence of Pln/Hspg2 gene mutation is the
disorganization of the chondrocytic columnar arrangement and expansion of the
hypertrophic zone in Pln mutants relative to controls. The lack of upregulation of BiP in
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mutant chondrocytes indicates that it is unlikely that endoplasmic reticulum (ER) stress and
the unfolded protein response (UPR) occur as a result of Pln retention in the ER of mutant
chondrocytes. In addition, the residual amounts of Pln in the ER of mutant chondrocytes did
not influence secretion levels of other proteoglycans important in cartilage function such as
aggrecan. Thus, the observed disorganization of mutant growth plates is believed to be
directly associated with the lack of Pln secretion in the cartilage matrix of mutant bones
rather than an abnormal retention of Pln in the ER. This phenotype is fully consistent with
previous observations and confirms that mice with hypomorphic mutations in the Pln/Hspg2
gene are viable and can be used as preclinical models to study Pln function during
skeletogenesis and bone aging disease such as osteoporosis and osteoarthritis [19]. Because
osteoprogenitors that do not secrete large amounts of Pln in the extracellular space were
found to have an increased potential to differentiate, we suggest that the observed in vitro
phenotype results from the unleashing of HBGFs that are normally sequestered by HS
chains present in the extracellular matrix. Similarly, during endochondral ossification the
altered organization of the chondrocyte territorial matrix observed in the absence of Pln may
allow increased diffusion of HBGFs from the periosteal compartment, a signal that is
eventually associated with enhanced bone formation and mineral apposition. This idea is
consistent with the established function of HSPGs in the establishment of HBGF gradients
as well as Pln preferential and elevated expression at interfaces where a barrier is required
(i.e., basement membranes, chondro-osseous junction in the growth plate) [2, 17]. In other
loss-of-function models of proteoglycan function, the absence of biglycan and decorin in
developing bone prevented TGF-β from proper sequestration within the ECM and enhanced
interaction with its signaling receptors [23]. Similarly, excess of unbound BMP2 in
developing Pln mutant bone may overactivate signaling pathways in progenitors and
enhance terminal differentiation and mineralization. Consistent with this idea, proteoglycans
and HS can function as potent inhibitors of hydroxyapatite formation [24, 25]. Interestingly,
reduced levels of Pln also were found to be associated with vascular calcification of smooth
muscle cells in the aorta of an experimental rat model [26], suggesting that Pln interaction
with factors that promote calcification can protect various tissue types from pathological
mineralization. Furthermore, recent data consistent with this study showed that Pln
deficiency is associated with a decrease in osteocytes’ pericellular space which suggested
that Pln and its HS chains prevent tissue mineralization [17]. Additionally, Pln was found to
interact directly with calcium phosphate mineral in bovine bone extracts [27]. Thus, we
propose that the lack of Pln secretion in developing Pln hypomorph bones increases
mineralization due to elevated availability of unbound HBGFs that, in turn, is associated
with bone widening/shortening.
We demonstrated that adult Pln mutant mice exhibit dwarfism with severe spine deformity,
facial flattening, deformation of the hip, and long bone widening and shortening with no
concomitant bone weight decrease. A recent study from our group that used 3.5-month-old
mice of the same model demonstrated that Pln mutant bones did not respond to the same
extent as age-matched controls when subjected to tibial axial loading due to reduced
mechanosensation by the compromised pericellular matrix of Pln mutant osteocytes [18].
These data as well as previous work from others provide strong genetic evidence that Pln is
essential for normal skeletal patterning and also plays an important function in the
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maintenance of skeletal integrity and response to load during adulthood [3, 19, 28].
Additionally, even though only residual levels of Pln are secreted in developing bones, the
presence of reduced amounts of Pln in basement membranes of Pln mutant tissues (heart,
kidney and skeletal muscles) is sufficient to prevent perinatal lethality and to allow mutants
to reach adulthood [19, 28]. These observations are consistent with the skeletal phenotype of
SJS type 1 patients [5].
While both male and female bones were significantly shorter and displayed increased cross-
sectional parameters relative to controls, the periosteal expansion was more severe in
females relative to males. Although gender influenced the genotype effect on cortical bone
parameters the mechanisms involved are currently unknown. Gender-specific effects are
typically observed at skeletal maturity and male bones are known to have better adaptation
capacities than female bones [29]. In the current study, increase in cortical bone mineral
content was more pronounced in Pln mutant females than in Pln mutant males. A gender-
specific bone phenotype was also found in mutant mice displaying a loss-of-function
mutation in the biglycan (Bgn) gene encoding for a proteoglycan involved in the
differentiation of osteoblast precursor cells [13]. In contrast to the Bgn gene, the Pln/Hspg2
gene does not lie on one of the two sexual chromosomes, and the cause of sexual
dimorphism observed in this study will require further investigations.
As predicted from cross-sectional geometrical parameters, Pln mutant female bones failed
under significantly higher loads, displayed significantly reduced PYD, and greater elastic
modulus than Pln mutant male bones. This result is consistent with increased cortical BMD
when compared to controls and indicates that Pln mutant female bones became more brittle.
In contrast, Pln mutant male bones displayed compensable bending rigidity during elastic
deformation and non-significant change in both PYD and E when compared to controls.
Other studies with genetic models displaying a short stature phenotype due to growth plate
anomalies also demonstrated that males were able to restore overall bone stiffness to control
levels in the femur whereas females were not [11, 13]. Thus, in males elevated BMD is
believed to compensate for decreased geometry while preserving cortical bone structural
integrity.
Bone microarchitecture and composition are known to be co-regulated during bone
formation in order to produce adequate mechanical properties that are well adapted for
future load conditions [30, 31]. Thus, genetic perturbation altering Pln secretion in the
cartilage matrix that serves as a template for bone formation leads to dwarfism and
suboptimal bone quality in adults. Dysregulation of bone morphogens availability due to
absence of Pln in the developing cartilage matrix may explain alteration in adult bone
mechanical properties. Increase of material properties via mineralization to compensate for
decreased geometric properties is not new and is observed in many other models often at the
expense of bone quality [11, 13, 32]. Although stiffness in three-point-bending is closely
correlated to mineralization, the control of collagen fiber orientation and cross-linking by
non-collagenous proteins such as HSPGs can also contribute to overall changes in bone
material properties. Additionally, HSPGs are believed to play a direct role in
biomineralization as inhibitors and differential expression in females may result in
regulation of mineral growth and crystallinity. Gender-specific variations in bone mineral
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properties have been reported in other genetically-altered mouse models such as estrogen-
receptor β or androgen-receptor deficient mice, but these molecules are responsible for
interactions with sex hormones so gender effects are expected [33, 34]. Recent work
performed in skin tissues demonstrated that a severe reduction of Pln expression occurs
specifically in aging women epidermis but not age-matched men [35]. Previous studies
performed in mouse blastocysts showed that Pln expression increased with acquisition of
attachment competence as a result of estrogen stimulation [36]. Such studies support the
idea that gene expression of Pln may be regulated by estrogen and that gender-specific
response in Pln mutant bones is somehow connected to sex hormone signaling, a possibility
which will require further studies.
In conclusion, our results show that, severe reduction of Pln is primarily associated with
increased osteogenesis and an enhanced bone mineralization phenotype. The decrease in
adult Pln mutant bone quality indicates that Pln-deficient mice constitute a unique model for
understanding the relationship between regulation of growth factor signaling by matrix
components and risk for bone fracture.
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Figure 1. Pln is not secreted in developing Pln mutant growth plates and co-localizes with the
ER-resident protein BiP in a perinuclear intracellular compartment
Pln (red) extracellular deposition is severely decreased in Pln mutant (F-J) versus WT (A-E).
Pln signal (red) is retained intracellularly in the proliferating zone of Pln mutants (F-G) and
co-localizes with BiP signal (yellow in H) whereas signals for these two proteins did not
overlap in WT (Pln in red and BiP in green in C). Columnar arrangement of chondrocytes in
WT prehypertrophic and hypertophic zones (D) is lost in Pln mutants (I) as indicated by the
disorganized aggrecan staining of the cartilage matrix in Pln mutant growth plates (compare
green in D and I). Despite changes in matrix organization the overall secretion of aggrecan
remained undisturbed in mutant vs. WT growth plates (compare green in E and J). Arrow in
A and F indicate an increase in the diameter of Pln mutant developing bones relative to WT.
Arrowhead in F points to reduced deposition of Pln in the basement membrane of a blood
vessel present in tissue surrounding developing bone. Magnification bars: 200 μm (A, E, F,
J), 50 μm (B, G), 10 μm (C, H), and 100 μm (D, I). The images shown are representative of
immunolabelings performed on growth plates of newborn mice (n=5 per genotype)
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Figure 2. Pln mutant hypertrophic zone is disorganized and expanded
Type X collagen (green) immunolabeled area overlaps with calcified deposits detected using
the von Kossa method in mutant (C and D) but not in WT (A and B).
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Figure 3. In vitro secretion of Pln by cultured bone progenitors prevents spontaneous
differentiation, and inhibits BMP2-induced differentiation into calcifying osteoblast-like cells
Lack of extracellular expression of Pln in Pln mutants (green in B) is accompanied by
increased in vitro differentiation of osteoprogenitors relative to WT (compare alkaline
phosphatase activity in purple in D and C). This effect is enhanced in the presence of BMP2
(compare F to E) and in vitro mineralization can be clearly detected in Pln mutant cultures
treated with BMP2 during 12 days of culture (J) whereas no mineral deposits are found in
WT cultures subjected to the same culture conditions. Images representative of three
biological replicates are shown.
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Figure 4. Pln mutant display a short stature phenotype and mild skeletal deformities that are not
associated with a decrease in skeletal bone mass
Postnatal growth curves (A) of WT, heterozygous, and Pln mutant littermates (n≥5 for each
genotype). Pln mutants display a considerable growth deficiency when compared with WT
and heterozygous controls of the same gender. Representative x-ray image areas of
skeletally mature (control) and age-matched mutant hindlimbs (B) showed diminished
length of long bones and vertebrae in Pln mutants vs. controls (see arrows). * in B indicates
deformity of the ischium in Pln mutants. Mid-diaphyseal cross-sections at mid-shaft showed
an increase in the bone area of mutant animals compared to gender-matched controls that
was more pronounced in females than in males (C). Bone measurements showed significant
decrease in Pln mutant bone length relative to wild type in all long bones examined
regardless of gender (D). In contrast, wet bone weight was only significantly increased in
Pln mutant male femora compared to wild type male femora (E). ***, **, and * indicate
significant differences (p<0.001, p<0.01, and p<0.05, respectively) in Pln mutant relative to
controls.
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Figure 5. High bone mineral density in Pln mutant bones is associated with increased brittleness
Bending rigidity (EI), ultimate force, and PYD of Pln mutant and WT femurs were obtained
from three-point-bending deformation curves. BMD and medial-lateral moment of inertia
(IML) were obtained from μCT scans. Young’s moduli (E) were calculated using EI and IML.
Changes in bone material properties are more pronounced in Pln mutant females than in Pln
mutant males when compared to gender-matched controls. *p<0.05, n≥6; n.s. non
significant.
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Table 1
Cross-sectional Cortical Properties at Femoral Mid-Shaft
Males Females
WT (n=6) Perlecan mutants (n=6) %change vs.
WT
WT (n=7) Perlecan mutants (n=6) %change vs.
WT
Inner Perimeter (mm) 4.18 (±0.13) 4.26 (±0.23) +2.1% 4.04 (±0.09) 4.12 (±0.11) +2.1%
Outer Perimeter (mm) 5.60 (±0.11) 5.74 (±0.24) +2.7% 5.25 (±0.11) 5.63 (±0.15) +7.2%
Marrow Area (mm2) 1.17 (±0.06) 1.3 (±0.15) +10.9% 1.18 (±0.04) 1.22 (±0.05) +3.8%
Cortical Area (mm2) 1.00 (±0.06) 1.12 (±0.09) +12.1% 0.87 (±0.07) 1.12 (±0.04) +29.3%
Total Area (mm2) 2.17 (±0.04) 2.42 (±0.216) +11.5% 2.04 (±0.08) 2.34 (±0.06) +14.6%
BMD (mg/cc) 990.8 (±28.5) 1072.6 (±42.5) +8.3% 984.0 (±51.6) 1073.3 (±39.4) +9.1%
BMC (mg) 0.019 (±0.002) 0.024 (±0.002) +20.7% 0.017 (±0.001) 0.024 (±0.001) +40.2%
A/P diameter (mm) 1.31 (±0.06) 1.52 (±0.08) +16.2% 1.39 (±0.05) 1.54 (±0.07) +10.6%
M/L diameter (mm) 2.10 (±0.09) 2.02 (±0.06) -3.5% 1.90 (±0.09) 1.96 (±0.11) +3.6%
Cortical width (mm) 0.22 (±0.02) 0.23 (±0.01) +5.5% 0.21 (±0.02) 0.25 (±0.02) +19.5%
Ixx=IML (mm4) 0.255 (±0.035) 0.317 (±0.067) +24.5% 0.235 ( ±0.053) 0.344 (±0.063) +46.4%
Iyy=IAP (mm4) 0.304 (±0.091) 0.351 (±0.084) +15.6% 0.211 (±0.051) 0.291 (±0.047) +37.5%
Bold % changes are significant, p<0.05. BMD, bone mineral density; BMC, bone mineral content; A/P, anterior-posterior; M/L, medio-lateral
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